{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:48:24Z","timestamp":1792727304304,"version":"4.5.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/cco.0000000000000065","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T11:55:26Z","timestamp":1394711726000},"page":"259-264","source":"Crossref","is-referenced-by-count":151,"title":["Biomarkers in prostate cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"David A.","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013.","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archinte.162.17.1985","article-title":"Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology and End Results) Program population-based study.","volume":"162","author":"Clegg","year":"2002","journal-title":"Arch Intern Med"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CCO.0b013e32835eb5d1","article-title":"Biological determinants of health disparities in prostate cancer.","volume":"25","author":"Martin","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0090-4295(02)01960-X","article-title":"Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.","volume":"60","author":"Paquette","year":"2002","journal-title":"Urology"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"e9584","DOI":"10.1371\/journal.pone.0009584","article-title":"Declining death rates reflect progress against cancer.","volume":"5","author":"Jemal","year":"2010","journal-title":"PLoS One"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/era.12.154","article-title":"Screening for prostate cancer: an updated review.","volume":"13","author":"Marta","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.28238","article-title":"Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy.","volume":"119","author":"Trantham","year":"2013","journal-title":"Cancer"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","article-title":"Time trends and local variation in primary treatment of localized prostate cancer.","volume":"28","author":"Cooperberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40291-013-0014-y","article-title":"Assays for prostate cancer.","volume":"17","author":"Hansen","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3343\/alm.2013.33.4.233","article-title":"Is prostate-specific antigen effective for population screening of prostate cancer A systemic review.","volume":"33","author":"Lee","year":"2013","journal-title":"Ann Lab Med"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/bjc.2012.400","article-title":"International multicenter study examining selection criteria for active surveillance in men undergoing radical prostatectomy.","volume":"107","author":"Wong","year":"2012","journal-title":"Brit J Cancer"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/pros.22459","article-title":"The epigenetic promise for prostate cancer diagnosis.","volume":"72","author":"Van Neste","year":"2012","journal-title":"Prostate"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.urology.2011.10.058","article-title":"We need a better marker for prostate cancer. How about renaming PSA.","volume":"79","author":"Vickers","year":"2012","journal-title":"Urology"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1559-0275-10-13","article-title":"Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.","volume":"10","author":"Fuzery","year":"2013","journal-title":"Clin Proteom"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1464-410X.2012.11329.x","article-title":"From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.","volume":"112","author":"Hori","year":"2013","journal-title":"BJU Int"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.juro.2012.11.149","article-title":"Prospective multicenter evaluation of the Beckman Coulter prostate health index using WHO calibration.","volume":"189","author":"Loeb","year":"2013","journal-title":"J Uro"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.urology.2013.10.016","article-title":"Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform -2proPSA(p2PSA), p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10ngmL and normal digital rectal examination.","volume":"38","author":"Lazzeri","year":"2014","journal-title":"Urology"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.12217","article-title":"Clinical performance of serum prostate-specific antigen isoform -2proPSA (p2PSA) and its derivatives p2PSA and the prostate health index (phi) in men with a family history of prostate cancer: results from a multicenter European study, the PROMEtheuS project.","volume":"112","author":"Lazzeri","year":"2013","journal-title":"BJU Int"},{"key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/pcan.2013.50","article-title":"-2proPSA is an early marker for prostate cancer aggressiveness.","volume":"17","author":"Heidegger","year":"2014","journal-title":"Prostate Cancer and Prostatic Disease"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.juro.2013.02.3184","article-title":"Head to head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.","volume":"190","author":"Scattoni","year":"2013","journal-title":"J Urol"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-10-0007","article-title":"A prospective, multicenter, National Cancer Institute Early Detection Research Network study of -2proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.","volume":"19","author":"Sokoll","year":"2010","journal-title":"Cancer Epidemol Biomarkers Prev"},{"key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.juro.2012.07.023","article-title":"Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1962 cases.","volume":"188","author":"Crawford","year":"2012","journal-title":"J Urol"},{"key":"R27-5-20210128","first-page":"447","article-title":"Urinary prostate cancer 3 test: toward the age of reason U","volume":"75","author":"Vlaeminck-Guillem","year":"2010","journal-title":"rology"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","article-title":"Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.","volume":"60","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/1471-2164-14-690","article-title":"Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.","volume":"14","author":"Knezevic","year":"2013","journal-title":"BMC Genom"},{"key":"R30-5-20210128","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.2012.39","article-title":"Prognostic value of cell cycle progression signature for a prostate cancer death in a conservatively managed needle biopsy cohort.","volume":"106","author":"Cuzick","year":"2012","journal-title":"Brit J Cancer"},{"key":"R31-5-20210128","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijrobp.2013.04.043","article-title":"Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.","volume":"86","author":"Freedland","year":"2013","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"R32-5-20210128","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","article-title":"Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.","volume":"31","author":"Cooperberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"R33-5-20210128","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/pros.22704","article-title":"Metabolomic signatures of aggressive prostate cancer.","volume":"73","author":"McDunn","year":"2013","journal-title":"Prostate"},{"key":"R34-5-20210128","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1158\/1078-0432.CCR-11-3209","article-title":"Prospective study of changes in the metabolomics profiles of men during their first three months of androgen deprivation therapy for prostate cancer.","volume":"18","author":"Saylor","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R35-5-20210128","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/ijc.28303","article-title":"Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma.","volume":"133","author":"Jung","year":"2013","journal-title":"Int J Cancer"},{"key":"R36-5-20210128","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11306-012-0452-2","article-title":"Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry.","volume":"9","author":"Kami","year":"2013","journal-title":"Metabolomics"},{"key":"R37-5-20210128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.juro.2012.04.143","article-title":"Toward the detection of prostate cancer in urine: a critical analysis.","volume":"189","author":"Truong","year":"2013","journal-title":"J Urol"},{"key":"R38-5-20210128","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/bmm.13.105","article-title":"ERG protein expression as a biomarker of prostate cancer.","volume":"7","author":"Falzarano","year":"2013","journal-title":"Biomarkers Med"},{"key":"R39-5-20210128","first-page":"259","article-title":"Molecular diagnosis of prostate cancer: are we up to age Semin O","volume":"40","author":"Bhavsar","year":"2013","journal-title":"ncol"},{"key":"R40-5-20210128","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.urolonc.2011.04.001","article-title":"Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.","volume":"31","author":"Salami","year":"2013","journal-title":"Urol Oncol"},{"key":"R41-5-20210128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22563","article-title":"Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.","volume":"73","author":"Cornu","year":"2013","journal-title":"Prostate"},{"key":"R42-5-20210128","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2012.11.014","article-title":"Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.","volume":"65","author":"Leyten","year":"2014","journal-title":"Eur Urol"},{"key":"R43-5-20210128","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1515\/cclm-2011-0935","article-title":"DNA methylation biomarkers and their utility for solid cancer diagnostics.","volume":"50","author":"Heichman","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"R44-5-20210128","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.juro.2012.08.219","article-title":"Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.","volume":"189","author":"Stewart","year":"2013","journal-title":"Urol"},{"key":"R45-5-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.juro.2012.08.188","article-title":"CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer.","volume":"189","author":"Desotelle","year":"2013","journal-title":"Urol"},{"key":"R46-5-20210128","first-page":"213","article-title":"Mitochondria, prostate cancer, and biopsy sampling error.","volume":"15","author":"Parr","year":"2013","journal-title":"Discov Med"},{"key":"R47-5-20210128","doi-asserted-by":"crossref","first-page":"612369","DOI":"10.1155\/2013\/612369","article-title":"Mitochondria and cancer: past, present, and future.","volume":"2013","author":"Verschoor","year":"2013","journal-title":"Biomed Res Int"},{"key":"R49-5-20210128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2013.04.040","article-title":"Predictive value of four kallikrein markers for pathologically insignificant compared to aggressive prostate cancer in radical prostatectomy specimens: results from the European randomized study of screening for prostate cancer section Rotterdam.","volume":"64","author":"Carlsson","year":"2013","journal-title":"Eur Urol"},{"key":"R50-5-20210128","first-page":"700","article-title":"Next-generation prostate-specific antigen test: ready to use Eur U","volume":"64","author":"Bjartell","year":"2013","journal-title":"rol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:44Z","timestamp":1620950144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201405000-00005"}},"subtitle":["what's new?"],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000065","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}